Stock listing
LS Exchange:A2DG6B Physiomics PLC Aktie
German listing (LS Exchange) of Physiomics PLC · home listing LSE:PYC
Follow Physiomics PLC into a list and get an email when it puts out news.
Home listing price · LSE:PYC
0.415p GBX (pence) 0.000 (0.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:PYC
- Day range
- 0.380p – 0.415p GBX (pence)Nov 20, 2026
- Volume
- 1.72M sharesNov 20, 2026
- Market cap
- £1.88M GBPAt the close on Nov 20, 2026 · price × 453.2M shares outstanding
- 52-week range
- 0.253p – 0.800p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £14,664 GBPMedian day 1.28M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:PYC · Home | 0.415p GBX (pence) | 0.000 (0.0%) | 1,724,176 | 0.415p | 0.415p | 0.380p | 0.415p | Close on Nov 20, 2026 |
| Frankfurt:RVW1 | €0.0005 EUR | -0.0005 (-50.0%) | — | €0.0005 | €0.0005 | €0.0005 | €0.0010 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:PYC · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.415p | 0.000 | 0.0% | 0.415p | 0.415p | 0.380p | 1,724,176 | |
| 0.415p | 0.000 | 0.0% | 0.415p | 0.415p | 0.386p | 2,050,000 | |
| 0.415p | -0.010 | -2.4% | 0.415p | 0.415p | 0.386p | 2,050,000 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.425p | 0.400p | 487,456 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.429p | 0.400p | 3,079,464 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.429p | 0.403p | 414,621 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.425p | 0.403p | 90,310 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.430p | 0.400p | 233,500 | |
| 0.425p | +0.005 | +1.2% | 0.420p | 0.435p | 0.403p | 675,951 | |
| 0.420p | +0.010 | +2.4% | 0.415p | 0.435p | 0.380p | 459,882 | |
| 0.410p | 0.000 | 0.0% | 0.410p | 0.430p | 0.370p | 2,706,116 | |
| 0.410p | -0.015 | -3.5% | 0.415p | 0.415p | 0.375p | 3,083,473 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.425p | 0.400p | 1,005,526 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.450p | 0.403p | 1,370,323 | |
| 0.425p | 0.000 | 0.0% | 0.425p | 0.438p | 0.411p | 3,261,089 | |
| 0.425p | -0.050 | -10.5% | 0.450p | 0.450p | 0.400p | 14,142,077 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.475p | 0.430p | 6,902,457 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.475p | 0.451p | 595,612 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.475p | 0.470p | 116,198 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.475p | 0.451p | 200,001 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 195,895 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.475p | 34 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 971,692 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 1,134,827 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 2,002,172 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 522,766 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.453p | 2,657,632 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.472p | 949,829 | |
| 0.475p | 0.000 | 0.0% | 0.475p | 0.500p | 0.450p | 122,004 | |
| 0.475p | -0.050 | -9.5% | 0.525p | 0.525p | 0.470p | 8,583,565 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.503p | 339,934 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.525p | 0.503p | 1,127,154 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.500p | 1,401,125 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.533p | 0.503p | 1,058,694 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.533p | 0.500p | 155,268 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.500p | 1,825,068 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.500p | 1,556,551 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.510p | 281,263 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.500p | 1,316,928 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.535p | 0.500p | 1,275,272 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.539p | 0.503p | 4,953,887 | |
| 0.525p | +0.050 | +10.5% | 0.500p | 0.550p | 0.500p | 26,053,755 | |
| 0.475p | -0.035 | -6.9% | 0.510p | 0.520p | 0.468p | 7,626,601 | |
| 0.510p | -0.015 | -2.9% | 0.525p | 0.535p | 0.480p | 9,347,897 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.525p | 0.525p | 1,702,733 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.530p | 0.500p | 2,991,992 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.500p | 529,252 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.525p | 0.500p | 6,910,912 | |
| 0.525p | 0.000 | 0.0% | 0.525p | 0.550p | 0.515p | 1,252,602 | |
| 0.525p | -0.025 | -4.5% | 0.550p | 0.600p | 0.500p | 1,602,000 | |
| 0.550p | -0.025 | -4.3% | 0.600p | 0.650p | 0.520p | 10,143,141 | |
| 0.575p | +0.050 | +9.5% | 0.534p | 0.600p | 0.534p | 8,091,847 | |
| 0.525p | +0.010 | +1.9% | 0.515p | 0.550p | 0.504p | 7,441,138 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.515p | 0.480p | 1,383 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.515p | 0.484p | 481,192 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.515p | 0.484p | 521,126 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.550p | 0.480p | 1,199,739 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.524p | 0.480p | 555,878 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.515p | 0.511p | 870,394 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.515p | 0.480p | 1,113,072 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.550p | 0.480p | 3,210,057 | |
| 0.515p | 0.000 | 0.0% | 0.515p | 0.524p | 0.483p | 2,814,292 | |
| 0.515p | +0.045 | +9.6% | 0.470p | 0.550p | 0.470p | 18,228,268 | |
| 0.470p | 0.000 | 0.0% | 0.470p | 0.475p | 0.447p | 1,888,647 | |
| 0.470p | 0.000 | 0.0% | 0.470p | 0.470p | 0.469p | 72,495 |
Splits
1 split · LSE:PYC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation |
- Ticker
- LS Exchange:A2DG6B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- LS Exchange
- Currency
- EUR
What changed lately
Latest news release · Nov 5, 2026
Result of AGM, Issue of Equity & TVR
Latest earnings call · Apr 9, 2026
Physiomics (LSE:PYC) — Investor Update
Replay and transcript
Latest news
Result of AGM, Issue of Equity & TVR
Nov 5, 2026
Closed 0.41p (0.0%) on Nov 5, 2026
Contract Award
Oct 20, 2026
Closed 0.475p (0.0%) on Oct 20, 2026
Contract Win and Commercial Opportunities
Oct 14, 2026
Closed 0.475p (0.0%) on Oct 14, 2026
Final Results & Notice of AGM
Oct 13, 2026
Closed 0.475p (0.0%) on Oct 13, 2026
Physiomics Awarded New Contract Wins
Sep 10, 2026
Closed 0.55p (-4.3%) on Sep 10, 2026
Physiomics Awarded Multiple New Contracts
Jul 8, 2026
Closed 0.475p (0.0%) on Jul 8, 2026
Appointment of Chief Operating Officer
Jul 1, 2026
Closed 0.475p (0.0%) on Jul 1, 2026
Proposed Issue of Equity and Grant of Options
Jun 30, 2026
Closed 0.475p (-5.0%) on Jun 30, 2026
Operations Update
Jun 26, 2026
Closed 0.475p (0.0%) on Jun 26, 2026
Hantavirus Translational Modelling Capability
May 28, 2026
Closed 0.675p (-3.6%) on May 28, 2026
Physiomics PLC on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 34 in the last 12 months · 267 in all · newest Nov 5, 2026 · oldest 2004
- Calls
- 12 calls with a replay · 12 with a transcript · latest Apr 9, 2026
- Decks
- 7 decks · latest Jan 29, 2024
Where Physiomics PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:PYC · Home listing | LSE | United Kingdom | GBX |
| LS Exchange:A2DG6B · This page | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2DG6B | Lang & Schwarz | Germany | EUR |
| Frankfurt:RVW1 | Frankfurt | Germany | EUR |
| Stuttgart:RVW1 | Stuttgart | Germany | EUR |
Valuation
EV/sales 1.6× against a median of 4.5×: 4th lowest of 8 Diagnostics & research services companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £1.46M GBP
- P/E
- Loss
- EV/sales
- 1.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.6×
- Gross margin
- −84.7%
- Operating margin
- −84.7%
- Net margin
- −74.1%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| SDS Optic Spolka Akcyjna · NEWCONNECT:SDS | US$3.81M | US$3.57M | n/a | 13.7× | n/a | 11.8× | −269.4% | 0.0× | n/a |
| genXone SA · NEWCONNECT:GX1 | US$3.47M | US$2.76M | n/a | 4.5× | 18.6× | 1.9× | −67.9% | 0.0× | n/a |
| Telo Genomics Corp. · TSXV:TELO | US$2.80M | US$2.12M | n/a | n/a | n/a | n/a | n/a | n/a | 0.04 |
| Advanced Biomed Inc. · NASDAQ:ADVB | US$2.73M | US$3.12M | 0.5× | 12.2× | n/a | 0.2× | n/a | 0.1× | 0.35 |
| Innovotech Inc. · TSXV:IOT | US$2.66M | US$2.51M | n/a | 1.0× | n/a | 1.5× | −21.1% | 0.1× | 0.39 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Median of the others | US$2.57M | US$2.32M | 15.1× | 4.5× | 16.3× | 1.7× | −67.9% | 0.0× | 0.35 |
Team and board
Officers
| Officer | Role |
|---|---|
| Peter Sargent | CEO |
| Jesse Thissen | COO & Head of Biometrics |
| Ian Bagnall | Finance Director & Company Secretary |
| Hayley Close | Head of Business Development |
| Michael Whitlow | Executive Director |
Board
| Director | Role |
|---|---|
| Nicholas Tulloch | Non-Executive Chair |
| Michael Whitlow | Executive Director |
Events
| Call | When | Status |
|---|---|---|
| Physiomics (LSE:PYC) — Investor Update | Thu, Apr 09, 2026 · 10:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Audited results for the year ended 30 June 2025, | Wed, Oct 01, 2025 · 7:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Interim Results | Mon, Mar 10, 2025 · 8:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Full Year Results | Mon, Oct 07, 2024 · 7:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Interim Results | Mon, Mar 18, 2024 · 8:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Business Update | Fri, Nov 17, 2023 · 8:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Investor Presentation | Thu, Apr 06, 2023 · 10:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Trading update | Wed, Jul 13, 2022 · 7:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Interim Results Update | Tue, Mar 08, 2022 · 9:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Full Year Results Presentation 2021 | Thu, Sep 30, 2021 · 9:00 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Physiomics (LSE:PYC) — Interim results for the six-month period ended 31 December 2020 | Thu, Mar 11, 2021 · 6:00 AM ET | Replay |
| Physiomics (LSE:PYC) — Final results for the year ended 30 June 2020 | Mon, Oct 05, 2020 · 6:00 AM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (January 2024) | Corporate update | 7 slides | Jan 29, 2024 |
| Physiomics Webinar 30 March 2023 | Conference | 19 slides | Mar 30, 2023 |
| H1 2021 Earnings Presentation | Earnings | 18 slides | Mar 12, 2021 |
| FY2020 Earnings Presentation | Earnings | 17 slides | Oct 6, 2020 |
| Biotrinity 2020 | Conference | 9 slides | April 2020 |
| BioTrinity 2019 | Conference | 10 slides | Apr 30, 2019 |
| BIO-Europe 2008 | Conference | 11 slides | Nov 19, 2008 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New Ordinary Shares (WRAP Retail Offer Shares) Closed: £70,000 raised · £0.005 a share · Winterflood Securities Ltd Dealers: Winterflood Securities Ltd Use of proceeds: Grow modelling and biostatistics consulting services, develop personalised dosing tool with DoseMe, and general working capital | Feb 17, 2025 | US$88,234 |
| Private placement of new ordinary shares Announced: £430,000 · £0.005 a share · Hybridan LLP Dealers: Hybridan LLP (lead) Use of proceeds: Growth of modelling and biostatistics consulting services, personalised medicine tool development, and general working capital | Feb 13, 2025 | US$538,089 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 941.2K | 784.0K | 543.3K | 597.4K | 830.3K | 702.3K | 799.1K | 783.1K | 512.9K | 270.5K |
| Cost of revenue | 1.74M | 1.27M | 1.22M | 1.18M | 1.26M | 1.07M | 976.2K | 961.8K | 770.1K | 759.7K |
| Gross profit | -797.2K | -435.1K | -677.4K | -581.6K | -429.0K | -365.8K | -177.1K | -178.7K | -257.2K | -489.2K |
| Research and development | 211.2K | |||||||||
| Selling, general and administrative | 11.3K | 11.3K | 11.0K | 10.5K | 10.5K | 14.0K | 14.4K | |||
| Operating income | -797.2K | -457.8K | -670.8K | -573.7K | -359.1K | -337.0K | -177.2K | -201.5K | -260.4K | -489.2K |
| Depreciation and amortization | 8.89K | 9.06K | 8.95K | 10.4K | 11.1K | 12.4K | 9.51K | 8.39K | 3.15K | 4.91K |
| EBITDA | -788.3K | -448.7K | -661.9K | -563.3K | -348.0K | -324.6K | -167.6K | -193.1K | -257.2K | -484.3K |
| Interest expense | 566 | 0 | 33 | 0 | 142 | 110 | 679 | 0 | 41 | 0 |
| Income before tax | -741.1K | -457.3K | -668.8K | -572.0K | -359.0K | -336.9K | -133.7K | -200.7K | -260.4K | -530.4K |
| Income tax | -44.0K | -42.0K | -59.4K | -94.8K | -105.8K | -121.1K | -69.3K | -96.7K | -77.1K | -129.9K |
| Net income | -697.0K | -415.3K | -609.4K | -477.3K | -253.1K | -215.8K | -64.4K | -104.0K | -183.3K | -400.5K |
| Earnings per share, basic | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 418.6K | 461.2K | 191.1K | 416.6K | 687.7K | 1.04M | 1.05M | 405.4K | 571.9K | 209.8K |
| Receivables | 342.4K | 363.3K | 150.9K | 244.4K | 410.0K | 260.7K | 383.2K | 103.8K | 50.4K | 37.3K |
| Inventory | 41.7K | -212.1K | 1 | -233.1K | 1 | 1 | ||||
| Current assets | 761.0K | 875.9K | 401.4K | 661.0K | 1.10M | 1.30M | 1.43M | 674.5K | 813.2K | 409.3K |
| Property, plant and equipment | 7.76K | 14.4K | 15.7K | 11.5K | 18.4K | 5.00K | 5.83K | |||
| Total assets | 788.6K | 892.0K | 422.6K | 674.4K | 1.12M | 1.32M | 1.45M | 694.3K | 818.2K | 415.2K |
| Accounts payable | 85.7K | 88.5K | 34.8K | 18.1K | 26.8K | 18.8K | 27.9K | 26.5K | 15.5K | 23.2K |
| Current liabilities | 264.6K | 199.9K | 140.1K | 142.7K | 140.6K | 157.6K | 131.5K | 86.4K | 128.2K | 86.9K |
| Total debt | 3.83K | 7.35K | ||||||||
| Total liabilities | 264.6K | 199.9K | 140.1K | 142.7K | 140.6K | 157.6K | 131.5K | 86.4K | 128.2K | 86.9K |
| Shareholders' equity | 524.0K | 692.2K | 282.5K | 531.7K | 974.8K | 1.17M | 1.31M | 607.9K | 690.0K | 328.3K |
| Shares outstanding | 345.5M | 238.2M | 135.4M | 97.4M | 97.4M | 97.1M | 73.7M | 71.9M | 59.1M | 51.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -561.7K | -546.1K | -548.1K | -264.9K | -349.3K | -32.5K | -115.7K | -143.8K | -169.8K | -437.3K |
| Capital spending | -4.43K | -3.94K | -17.3K | -6.63K | -9.37K | -16.2K | -5.09K | -21.8K | -2.33K | -6.80K |
| Free cash flow | -566.2K | -550.1K | -565.4K | -271.5K | -358.6K | -48.6K | -120.8K | -165.6K | -172.1K | -444.1K |
| Cash from investing | -4.43K | -3.41K | -15.2K | -6.22K | -9.37K | -16.2K | -5.09K | -22.7K | -2.29K | -6.65K |
| Cash from financing | 523.6K | 819.7K | 337.8K | 2.85K | 44.2K | 763.3K | 763.3K | 534.2K | 514.8K | |
| Share buybacks | 514.8K | |||||||||
| Change in cash | -42.6K | 270.2K | -225.5K | -271.1K | -355.8K | -4.41K | 642.5K | -166.5K | 362.1K | 70.8K |
Cap table
Built by 6ix from Physiomics PLC’s releases · as of Feb 17, 2025
- Common shares
- 453,208,718
- Fully diluted
- 453,208,718
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 453,208,718 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 453,208,718 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Hayley Close | Head of Business Development · Since at least May 27, 2026 |
| Ian Bagnall | Finance Director & Company Secretary · Since at least Oct 20, 2026 |
| Jesse Thissen | COO & Head of Biometrics · Since at least Oct 13, 2026 |
| Michael Whitlow | Executive Director · Since at least Oct 13, 2026 |
| Nicholas Tulloch | Non-Executive Chair · Since at least Apr 29, 2026 |
| Peter Sargent | CEO · Since at least Apr 29, 2026 |
Log in to ask 6ix AI your own questions about Physiomics PLC.